Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma (ccRCC) and the efficacy of salvage nivolumab/ipilimumab in patients with tumors unresponsive...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkins, Michael B., Jegede, Opeyemi A., Haas, Naomi B., McDermott, David F., Bilen, Mehmet A., Stein, Mark, Sosman, Jeffrey A., Alter, Robert, Plimack, Elizabeth R., Ornstein, Moshe, Hurwitz, Michael, Peace, David J., Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J., Braun, David, Einstein, David, Catalano, Paul J., Hammers, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426835/
https://www.ncbi.nlm.nih.gov/pubmed/35442713
http://dx.doi.org/10.1200/JCO.21.02938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426835/
https://www.ncbi.nlm.nih.gov/pubmed/35442713
http://dx.doi.org/10.1200/JCO.21.02938

Ejemplares similares